Akin Gump Advises ProKidney in Its $2.64 Billion Business Combination with Social Capital Suvretta Holdings Corp. III
Contact:
(New York) – ProKidney LP, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that it has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC), a special purpose acquisition company, for a combined equity value of $2.64 billion. Upon closing, the combined company will trade on the Nasdaq under the symbol "PROK." Akin Gump was among the firms that advised ProKidney in the deal.
The Akin Gump team representing ProKidney was led by partners Stuart Leblang and Jonathan Pavlich and included partner David Snyder, and counsel Eric Wexler and senior counsel Miriam Foley.
Akin Gump Strauss Hauer & Feld LLP is a leading international law firm with more than 900 lawyers in offices throughout the United States, Europe, Asia and the Middle East.
# # #
People Mentioned in This News
